Bausch Health Revenue Jumps to $10.3 Billion

By Chris Stiles • Thursday, February 19 16:05 • Permanent Link

Bausch Health Companies Inc. has recently released its 10-K report, offering a detailed look at its financial performance and operations. The company operates as a diversified specialty pharmaceutical and medical device company, with a focus on gastroenterology, hepatology, neurology, dermatology, generic pharmaceuticals, over-the-counter products, aesthetic medical devices, and eye health. Bausch Health operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb.

In 2025, Bausch Health reported revenues of $10,266 million, up from $9,625 million in 2024 and $8,757 million in 2023. The company's portfolio of products falls into five reportable segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. Bausch Health also announced plans to separate its eye health business, Bausch + Lomb, into an independent publicly traded entity. The company believes that the separation will unlock additional value and allow each entity to focus on its core businesses for sustained growth.

Regarding the company's capital structure, Bausch Health made significant refinancing transactions in 2025. This included entering into a credit agreement for new senior secured credit facilities and issuing senior secured notes to address debt obligations. The company also engaged in repurchase activities, retiring outstanding senior unsecured notes, and completed offers to exchange senior secured notes to reduce outstanding principal debt. These actions aimed to extend debt maturities and manage the company's capital structure effectively.

In terms of debt obligations, Bausch Health reported maturities and mandatory payments of its principal balances of debt obligations as of December 31, 2025. The total debt obligations for the years 2026 through 2030 and thereafter were outlined, providing transparency into the company's financial commitments. Additionally, the company terminated an accounts receivable credit facility, further shaping its capital structure.

Today the company's shares have moved -3.86% to a price of $6.98. If you want to know more, read the company's complete 10-K report here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.